Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-05

Clinical Trial Update: Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating radiolabeled monoclonal antibody HuJ591-GS (177Lu-J591) in metastatic prostate cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 177Lu-J591

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-10-05